Anzeige
Mehr »
Login
Montag, 05.06.2023 Börsentäglich über 12.000 News von 686 internationalen Medien
Vollgas-Montag! NuGen Medical: Kurs hebt ab!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 120159 | ISIN: US64049M2098 | Ticker-Symbol: NG9
Tradegate
05.06.23
15:05 Uhr
16,900 Euro
0,000
0,00 %
1-Jahres-Chart
NEOGENOMICS INC Chart 1 Jahr
5-Tage-Chart
NEOGENOMICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
15,40015,50022:02
15,40015,60022:00
ACCESSWIRE
281 Leser
Artikel bewerten:
(1)

NeoGenomics, Inc.: NeoGenomics to Host Investor Day on April 4, 2023

FT. MYERS, FL / ACCESSWIRE / March 27, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today that the Company will host an Investor Day on Tuesday, April 4, 2023, starting at 8:00 am ET. The event will feature a presentation by NeoGenomics' executive team members and conclude with a Q&A session.

Pre-register for the event here. A live webcast of the Investor Day presentation will be available online on the investor relations page of the Company's website at ir.neogenomics.com. A replay will be posted on NeoGenomics' website after the event and will be available for at least 30 days following.

About NeoGenomics, Inc.

NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world to help physicians diagnose and treat cancer.

NeoGenomics is committed to connecting patients with life altering therapies and trials. We believe that, together, with our partners, we can help patients with cancer today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to all applicable state and federal data protection laws, provides transparency and choice to patients regarding the handling and use of their data through expressed authorizations and our Notice of Privacy Practices, and has invested in leading technologies to ensure the data we maintain is secured at all times.

Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories in Fort Myers and Tampa, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; and CAP accredited laboratories in Cambridge, UK, Rolle, Switzerland, and China. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.

Contact:

NeoGenomics, Inc.
Kendra Sweeney
Vice President, Investor Relations and Communications
Kendra.Sweeney@neogenomics.com
T: +1-239-877-7474

SOURCE: NeoGenomics, Inc.

View source version on accesswire.com:
https://www.accesswire.com/745634/NeoGenomics-to-Host-Investor-Day-on-April-4-2023

Das ultimative Rendite-Paket für unruhige Zeiten
Big Pharma Boom! Stabile Erträge, günstige Bewertung. Chart-Profi Stefan Klotter hat für Sie exklusiv fünf Blue Chips aus der Pharma-Branche gefunden. Jetzt kostenlos herunterladen!
Hier klicken
© 2023 ACCESSWIRE
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.